HOME >> BIOLOGY >> NEWS
Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair

t and repair the brain and spinal cord from injury," says Moses Rodriguez, M.D., Professor of Neurology and Immunology at Mayo Medical School.

Acorda Therapeutics, a privately held biotechnology company, is developing therapies for spinal cord injury (SCI) and related neurological conditions, including multiple sclerosis (MS). The Company's lead product, Fampridine-SR, is in Phase 3 clinical trials for chronic SCI and Phase 2 for MS. Acorda's technology platform includes two remyelinating agents in preclinical development for MS. The first is M1, a class of human monoclonal antibodies, and the second is GGF2, a product of the neuregulin 1 gene. Both agents have been shown to restore myelin in the brain and spinal cord in animal models of MS. Additionally, Acorda is developing protein- and stem cell-based technologies for regeneration and repair of the spinal cord and brain. In 2002, Acorda was the recipient of the National Spinal Cord Injury Association's L. W. Freeman Award for scientific research.


'"/>

Contact: Tierney Saccavino, Acorda Therapeutics
tsaccavino@acorda.com
914-347-4300
Porter Novelli
20-Dec-2002


Page: 1 2

Related biology news :

1. Acorda Therapeutics acquires CeNeS neuregulin products
2. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
3. Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury
4. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director
5. Molecular therapeutics advance fight against brain cancer
6. Conflicting views on embryonic and adult stem cells complicate research in stem cell therapeutics
7. Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
8. Immerge biotherapeutics identifies miniature swine that do not transmit pig retrovirus to humans
9. Polymer gel holds promise for therapeutics delivery and tissue engineering
10. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
11. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today announced ... the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department ... scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement ...
(Date:7/18/2020)... ... July 17, 2020 , ... Commercial launch readiness is a critical stage ... a COVID cure or vaccine, the global economic downturn will only increase price pressures ... going away and capturing full value from every product launch is critical. However, history ...
(Date:7/2/2020)... (PRWEB) , ... July 01, 2020 , ... ... presented its phase 1a findings of Neihulizumab, a biologic for the treatment of ... June 2020. Led by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... HOUSTON (PRWEB) , ... August ... ... a biopharmaceutical cold chain validation engineering firm, is making available for ... driving the need to incorporate concurrent transport simulation testing into today’s biologics ...
(Date:8/7/2020)... Texas (PRWEB) , ... August 06, 2020 , ... ... and DNA vaccine industries, announces it has closed on the purchase of greenfield ... Park in Conroe, TX and includes over 21 acres in the initial acquisition, ...
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics ... , Known as MediVet Biologics since its formation in 2016, the company ... Ardent Animal Health will build on its base of innovative therapies for osteoarthritis and ...
(Date:7/31/2020)... ... 29, 2020 , ... G-CON Manufacturing, the leader in off-site ... FOR LIFE.” The adoption of this taglines comes at a time of tremendous ... to provide patients with urgently needed vaccines and other lifesaving pharmaceutical treatments. G-CON’s ...
Breaking Biology Technology:
Cached News: